论文部分内容阅读
目的分析输卵管妊娠联合应用甲氨蝶呤及米非司酮治疗的临床疗效。方法将2012年10月至2014年11月间收治的70例输卵管妊娠患者随机分为A及B两组,A组给予单纯甲氨蝶呤治疗,B组则给予联合甲氨蝶呤及米非司酮治疗,每组35例。对比两组临床治疗效果。结果 B组血β-HCG恢复正常时间及住院时间分别为(15.27±2.38)d及(15.27±2.11)d,均明显短于A组的(18.17±2.12)d及(17.61±2.23)d,差异有统计学意义(P<0.05)。同时B组临床治愈率为74.28%,明显高于A组的42.76%(P<0.05)。B组的药物不良反应发生率为14.29%,A组为17.14%,两组比较未见统计学差异(P>0.05)。结论甲氨蝶呤及米非司酮联合应用可显著提高输卵管妊娠的临床治疗效果。
Objective To analyze the clinical efficacy of tubal pregnancy combined with methotrexate and mifepristone. Methods Seventy patients with tubal pregnancy who were treated between October 2012 and November 2014 were randomly divided into two groups: A and B, methotrexate alone, and methotrexate combined with metmycine in group B Division ketone treatment, 35 cases in each group. Comparison of two groups of clinical treatment. Results The recovery time and hospital stay of β-HCG in group B were (15.27 ± 2.38) d and (15.27 ± 2.11) days, respectively, which were significantly shorter than those in group A (18.17 ± 2.12) days and (17.61 ± 2.23) days, The difference was statistically significant (P <0.05). At the same time, the clinical cure rate in group B was 74.28%, which was significantly higher than that in group A (42.76%, P <0.05). Adverse drug reaction rate in group B was 14.29%, in group A was 17.14%. There was no significant difference between the two groups (P> 0.05). Conclusion Combination of methotrexate and mifepristone can significantly improve the clinical efficacy of tubal pregnancy.